Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAPE Trial: Gemcitabine, Cisplatin, Nivolumab plus Tamibarotene in First-Line Urothelial Carcinoma
jRCT2041250017Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tamibarotene, nivolumab, gemcitabine and cisplatin in transitional cell carcinoma (TCC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Response rate (RR). Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2041250017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250017.